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Strengths and limitations of this study
 ► The scoping review design was able to provide 
collated and comprehensive insights into the 
peer- reviewed scientific literature on the topic, 
and included a wide scope of factors influencing 
active case- finding (ACF) policy development and 
implementation.
 ► The review may have provided a more in- depth 
insight into the topic by including additional data-
bases, searching grey literature and references of 
included studies, and contacting authors for more 
information.
 ► We did not do a critical appraisal of the individual 
sources of evidence or within sources of evidence, 
nor did we describe sources of funding for the in-
cluded articles.
 ► We limited the inclusion to studies written in English.
 ► Reporting of ACF policy development and implemen-
tation varied in completeness across the included 
articles, and as such, our data are limited by the 
details described in the literature.
AbStrACt
Objective To explore antecedents, components and 
influencing factors on active case- finding (ACF) policy 
development and implementation.
Design Scoping review, searching MEDLINE, Web of 
Science, the Cochrane Database of Systematic Reviews 
and the World Health Organization (WHO) Library 
from January 1968 to January 2018. We excluded 
studies focusing on latent tuberculosis (TB) infection, 
passive case- finding, childhood TB and studies about 
effectiveness, yield, accuracy and impact without 
descriptions of how this evidence has/could influence ACF 
policy or implementation. We included any type of study 
written in English, and conducted frequency and thematic 
analyses.
results Seventy- three articles fulfilled our eligibility 
criteria. Most (67%) were published after 2010. The studies 
were conducted in all WHO regions, but primarily in Africa 
(22%), Europe (23%) and the Western- Pacific region 
(12%). Forty- one percent of the studies were classified 
as quantitative, followed by reviews (22%) and qualitative 
studies (12%). Most articles focused on ACF for tuberculosis 
contacts (25%) or migrants (32%). Fourteen percent 
of the articles described community- based screening 
of high- risk populations. Fifty- nine percent of studies 
reported influencing factors for ACF implementation; 
mostly linked to the health system (eg, resources) and the 
community/individual (eg, social determinants of health). 
Only two articles highlighted factors influencing ACF policy 
development (eg, politics). Six articles described WHO’s 
ACF- related recommendations as important antecedent for 
ACF. Key components of successful ACF implementation 
include health system capacity, mechanisms for integration, 
education and collaboration for ACF.
Conclusion We identified some main themes regarding 
the antecedents, components and influencing factors for 
ACF policy development and implementation. While we 
know much about facilitators and barriers for ACF policy 
implementation, we know less about how to strengthen 
those facilitators and how to overcome those barriers. 
A major knowledge gap remains when it comes to 
understanding which contextual factors influence ACF 
policy development. Research is required to understand, 
inform and improve ACF policy development and 
implementation.
bACkgrOunD
Systematic screening for tuberculosis (TB) is 
defined by the World Health Organization 
(WHO) as the ‘systematic identification of 
people with suspected active TB, in a prede-
termined target group, using tests, exam-
inations or other procedures that can be 
applied rapidly’.1 Active case- finding (ACF) 
is synonymous with systematic screening 
for active TB, although it usually implies 
screening outside of health facilities. TB 
is a major global health challenge, partic-
ularly in low- income and middle- income 
countries. The WHO End TB Strategy and 
the Sustainable Development Goals aim 
at finding the ‘missing cases’ and ending 
the global TB epidemic by 2030. This will 
require intensified activity to increase TB 
case detection, specifically in ‘hard- to- reach’ 
groups.2 In 2019, there was a 3 million gap 
between estimated incident and notified 
TB cases globally, reflecting a combination 
of an underdiagnosis of cases and underre-
porting of cases who have been detected.3 
Many people with TB are diagnosed only 
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after long delays,4 causing suffering and economic hard-
ship for TB patients and TB- affected households, and 
sustained transmission.1
ACF is mostly provider- initiated. It targets people in 
high- risk groups who may not seek healthcare actively.1 
Potential benefits for patients include reduced morbidity, 
mortality and economic consequences due to earlier 
diagnosis, while society can benefit from reduced trans-
mission and a reduced burden of TB, which often affects 
the most economically productive members of a society. 
TB screening in high- risk groups has been implemented 
in many settings within the TB programme or in the 
context of research and can significantly improve TB case 
notification.5–7
However, if not well targeted and implemented, ACF 
can be costly leading to diversion and waste of scarce 
resources, potentially compromising passive case- 
finding infrastructure and weakening health systems. 
It can also cause harm to individuals, for example, by 
increasing the risk of a false positive diagnosis and 
providing TB treatment to individuals without TB, or 
increased stigma and discrimination arising from uncov-
ering TB, which need to be weighed against the benefit 
of identifying cases in the community that would other-
wise go untreated.1 2
Questions remain about both if ACF in general is worth-
while, and how to best plan and implement outreach 
screening through ACF in a given context as a synergistic 
way, that is, integrated into the healthcare system, and not 
delivered separately in a parallel system. The evidence base 
is weak concerning the benefits and cost- effectiveness of 
ACF and how it varies between risk groups.8 The strength 
of evidence to support alternative ACF approaches is 
low, with few head- to- head trial results being available 
to inform policy and practice. Many differences exist 
in stakeholders' values and preferences concerning the 
rationale, outcomes and possible secondary effects of 
ACF. Despite the relatively weak evidence, WHO has 
a guideline on systematic TB screening and the Global 
Fund9 and TB REACH10 provide increasing funding for 
ACF, while a growing number of countries are increasing 
investment in and have national policies for ACF. For 
example, Vietnam’s National Strategic Plan 2015–2020 
includes ACF in remote and congregate settings, and in 
high- risk groups including contacts, prisoners, miners, 
the elderly, homeless people, young adults, migrants, 
factory workers, communities, people living with HIV, 
multidrug- resistant patients, young males, smokers and 
intravenous drug users.11
The aim of this study was to explore antecedents, 
components and influencing factors for ACF policy devel-
opment and implementation, to inform and improve 
future ACF policy processes. We did not aim to review the 
evidence on ACF per se; therefore, we explore yield, accu-
racy and impact only in the context of how they influence 
ACF policy development or implementation.
MethODS
We conducted a scoping review, using an a- priori protocol 
based on the following research question: Which are the 
antecedents, components and influencing factors (barriers and 
facilitators) in developing and implementing ACF policies? 
The scoping review methodology was deemed appro-
priate given the breadth of the question. The protocol 
was based on guidance from the Joanna Briggs Methods 
Manual for Scoping Reviews.12 The inclusion criteria, 
the screening manual and the data- charting table were 
developed by one author (OB), reviewed by two authors 
(KV and KL) to ensure face validity, and pilot- tested. 
All team members were consulted at various stages of 
the scoping review to provide input on the search, data 
extraction and charting, and the interpretation of the 
results. The charted data were summarised in tables, and 
then condensed resulting in tables 1 and 2. The Preferred 
Reporting Items for Systematic reviews and Meta- Analyses 
Extension for Scoping Reviews (PRISMA- ScR) was used to 
guide reporting.13 The completed checklist is available in 
online additional file 1. The protocol is available from the 
corresponding author on request.
Data sources and search
We searched MEDLINE, Web of Science, The Cochrane 
Database of Systematic Reviews and the WHO Library 
from January 1968 (year of the first publication on ACF 
in MEDLINE) until January 2018. The search strategy 
was developed in collaboration with a medical librarian 
from Karolinska Institutet (Carl Gornitzki), and further 
refined through team discussion. The search strategy 
for MEDLINE is available in online additional file 2. 
The latter was standardised but adapted to fit the other 
database searches. The respective search strategies are 
available from the corresponding author on request. The 
results of the literature search were imported into Rayyan.
Inclusion criteria
Eligible studies focused on the detection of active TB 
disease. The review included studies describing or 
analysing ACF policy development and implementation. 
Facilitators and barriers linked to access or treatment were 
included, if there was a clear link to ACF. Furthermore, 
the review included studies analysing the use of evidence 
in ACF policy development and implementation. Studies 
of any design, conducted in any setting or country and 
those published in the English language were eligible for 
inclusion. We excluded studies focusing only on latent 
TB infection, passive case- finding and childhood TB, and 
studies about effectiveness, yield, accuracy and impact 
without descriptions of how this evidence has/could 
influence ACF policy. The inclusion of different ACF 
approaches implies that while many lessons can be learnt 
across different settings, some might not be generalisable.
Screening, data abstraction and charting
One reviewer (OB) initially reviewed titles to remove 
duplicates, and those studies not focusing on TB. Two 
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Table 1  Characteristics of the articles included in the scoping review (n=73)
Study characteristics References Number (%)
Year of publication
  1979 66 1 (1)
  1995–1999 51 53 58 67 4 (5)
  2000–2009 17 21 23 24 28 30 31 46–48 54 56 59 68–70 16 (22)
  2010–2018 14–16 18–20 22 25–27 29 32 33 35–42 44 45 49 50 52 55 57 60–65 71–83 85 49 (67)
Region
  Africa 14 20 22 35 41 42 44 45 60 62 63 65 66 73 82 85 16 (22)
  Americas (North America) 23 24 32 34 58 61 64 67 70 72 10 (14)
  Eastern Mediterranean 77 1 (1)
  Europe 28 30 38 43 46–48 52–55 59 68 69 81 83 84 17 (23)
  South- East Asia 50 51 63 80 86 5 (7)
  Western Pacific 15 16 31 36 39 40 63 75 76 9 (12)
  Global perspective 19 21 27 33 74 76 78 7 (10)
  Other* 17 29 49 71 4 (5)
Study design
  Quantitative 15 16 29–31 35–37 40 41 44 45 48–51 59 61 63–68 73 75 77 83 84 86 30 (41)
  Review 17–20 25 27 34 46 49 56 69 70 74 76 78 79 16 (22)
  Qualitative 14 22 23 38 43 54 55 62 71 9 (12)
  Descriptive 28 32 71 81 85 5 (7)
  Case study 26 58 72 3 (4)
  Mixed methods 39 42 2 (3)
  Other† 33 47 52 53 4 (5)
Target group
  Contacts 14 15 21 22 24 27 32 35–37 42 44 74–76 81 82 84 18 (25)
  Migrants
20 28 30 34 38 43 46–49 54–56 59 61 64 68 69 71 73 77 79 83
23 (32)
  Community 17 26 29 31 40 45 51 60 62 63 10 (14)
  High risk groups 19 25 33 57 66 5 (7)
  Homeless 23 53 58 67 4 (5)
  Asylum seekers or refugees 50 52 2 (3)
  People living with HIV 18 78 2 (3)
  Urban poor 16 39 2 (3)
  Other‡ 41 70 72 80 85 86 6 (8)
*High HIV prevalence countries,17 high TB incidence countries,29 low- burden countries.49 71
† Letter to editor,52 observational study,53 perspective33 and editorial.47
‡ Population affected by TB outbreak,72 pastoralists,41 healthcare workers,65 prisoners,80 people living in slums,86 street connected youth and young 
adults85 and non- immigrant visitors.70
reviewers (OB and KV) independently reviewed titles 
and abstracts, and then full- text articles for inclusion. 
Conflicts were resolved through discussion based on the 
inclusion/exclusion criteria.
The data- charting table was developed in Microsoft 
Excel. An abridged version of the table is available in 
online additional file 3. Data were extracted on study 
design, country, target population for ACF, benefits of 
ACF, risks of ACF, ACF antecedents, ACF policy develop-
ment and implementation (use of evidence, country- level 
to individual- level facilitators and barriers, stakeholders 
involved), lessons learnt, future perspectives and future 
research. Relevant data were charted by one author (OB), 
while a second author (KV) verified this step by charting 
data from a random sample of studies for comparison. 
Differences in data- charting were resolved by discussion.
Patient and public involvement
This study is related to a qualitative study of experts and 
a survey of National TB Programme managers combined 
with a policy document review on the topic of ACF policy 
development and implementation which are currently 
under way to harness tacit knowledge on the topic. The 
research questions and variables for these studies were 
Protected by copyright.
 o
n
 D
ecem
ber 12, 2019 at Nepal:BM
J-PG
 Sponsored.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031284 on 11 December 2019. Downloaded from 
4 Biermann O, et al. BMJ Open 2019;9:e031284. doi:10.1136/bmjopen-2019-031284
Open access 
Table 2  Barriers and facilitators for active case- finding policy implementation (n=43)
Reported factors References Number (%)
Health system level
  Limited financial resources 16 21 22 26 27 32 39 40 43 46 48 51 54 66 78 15 (35)
  Existing systems and structures 14 19 21 27 38 43 44 53 54 69 78 11 (26)
  Availability of diagnostic tests and services 16 19 27 34 41 49 50 66 8 (19)
  Staff experience, expertise, motivation 14 17 24 26 27 39–41 43 46 52 55 58 71 14 (33)
  Over- burdening staff 16 21 26 39 41 51 70 7 (16)
  Using person- centred approaches 14 22 23 27 34 43 53 65 8 (19)
  Collaboration and integration 14 16 18 34 39 43 52 7 (16)
  Health education 34 40–43 5 (12)
Health information and research system level
  Data, systems, supervision 19 24 27–29 42 48 7 (16)
Individual and community level
  Stigma and discrimination 14 22–25 27 28 31 37 38 43 50 58 59 77 82 16 (37)
  Individual characteristics 23 31 34 37 39 43 51 58 65 66 77 83 12 (28)
  Sociocultural factors 24 25 27 28 34 41 43 46 47 54 56 59 77 83 14 (33)
  Fear 23 24 34 38 39 43 53–56 10 (23)
  Mistrust 14 24 41 43 46 47 51 53 57 72 10 (23)
  Knowledge and awareness 14 23 24 26 37 43 53 58 8 (19)
informed by the results of this scoping review. The results 
of this study will be presented to researchers and policy- 
makers in the field via targeted issue briefs. We will also 
share the results with the public via a video and short 
messages on social media.
reSultS
literature search
After screening 2943 titles and abstracts and 271 full- 
text articles, 73 unique articles fulfilled our eligibility 
criteria (figure 1).14–86 The reasons for excluding full- 
text articles are provided in figure 1. What all included 
studies have in common is the goal of finding ‘missing’ 
TB cases through ACF, while the approaches vary greatly; 
from contact investigation to screening people in home-
less shelters (table 1). An example of a study included in 
this review is a qualitative study by Ayakaka et al, which 
explored influencing factors for TB contact investigation 
in Kampala, Uganda.14 The stakeholders who were inter-
viewed described key barriers for ACF as being limited 
knowledge about TB among contacts, stigma, mistrust of 
health centre staff among index patients and contacts, 
and high travel costs for lay health workers and contacts. 
At the same time, key facilitators for ACF comprised 
personalised and enabling services provided by lay health 
workers. To overcome barriers and strengthen facilita-
tors, the researchers identified education, incentivisation 
and restructuring of the service environment as relevant 
interventions.14
Characteristics of the included articles (n=73)
The breadth of studies identified reflect the complexity 
and diversity of ACF policies and their characteristics. 
There has been a gradual increase in the number of arti-
cles on ACF since the first identified (eg, from 1979), 
and 67% (n=49/73) were published in the period 2010–
2018 (table 1). The studies were conducted in all WHO 
regions, that is, the African region (22%, n=16/73), the 
Americas (North America) (14%, n=10/73), the Eastern 
Mediterranean region (1%, n=1/73), the European 
region (23%, n=17/73), South- East Asia (7%, n=5/73) 
and the Western Pacific region (12%, n=9/73). The most 
common types of articles were classified as quantitative 
papers (41%, n=30/73), reviews (22%, n=16/73) and 
qualitative studies (12%, n=9/73). The most frequent 
ACF target groups were contacts (25%, n=18/73) and 
migrants from high- incidence countries (32%, n=23/73), 
while 14% percent (n=10/73) of the articles focused 
on screening of defined communities. The remaining 
studies focused on different target groups which are 
specified in table 1.
Antecedents
ACF has been implemented for many decades primarily 
in high- income countries, starting with mass screening 
campaigns in the general population in the 1950s and 
1960s, then moving towards specific risk populations in 
recent decades, such as migrants from high- incidence 
countries and prison populations.15 In low- income 
and middle- income countries, the interest in ACF has 
increased in recent years, mainly as a response to a 
sustained case detection gap documented in annual 
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Figure 1 PRISMA flow diagram. ACF, active case- finding; PRISMA, Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses; TB, tuberculosis.
Global TB Reports produced by WHO3 and the emer-
gence of new WHO guidelines.16
Generally, TB programmes have moved from tradition-
ally vertical approaches and exclusively facility- based case- 
finding among people seeking care with TB symptoms 
(so called ‘passive case- finding’) towards being closer to 
the client through decentralised, community- based solu-
tions and outreach activities, including ACF—similar to 
community- based testing services that have increased 
access to HIV testing and care.17 18
In 1976, the WHO Expert Committee on TB recom-
mended that countries abandon indiscriminate mobile 
mass radiography, as evidence showed the inefficiency of 
population- wide screening in settings that had seen TB 
rates drop dramatically since the World War II.19 It should 
be noted that the Expert Committee emphasised that TB 
screening should still be done in selected risk groups.19 20
The current WHO guidelines on systematic screening 
for active TB were released in 2013.1 These guidelines 
still discourage indiscriminate mass screening and strongly 
recommend ACF only in selected high- risk groups, while 
conditionally recommending screening in other high- 
risk groups. Conditional recommendations are those for 
which the benefits are expected to outweigh the risks, 
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while the trade- offs, such as cost- effectiveness, feasibility 
or affordability may be uncertain. For example, WHO has 
made a conditional recommendation (very low- quality 
evidence) for screening certain clinical risk groups in 
settings where the TB prevalence is over 100 per 100 000 
population (while not recommending such screening 
in countries with a prevalence of less than 100 per 100 
000 population).1 The 2013 WHO guidelines—reflected 
in the latest 2015 WHO’s End TB Strategy2 and aligned 
with the Sustainable Development Goals—put ACF back 
on the agenda. The guidelines provide principles for how 
to test and expand an approach that had been largely 
missing in previous global TB strategies, including the 
Directly Observed Treatment, Short Course Strategy from 
199487 and the Stop TB Strategy 2006–2015 (although 
contact investigation and screening people living with 
HIV was included in the latter).88 Moreover, the guide-
lines emphasise the importance of basing ACF policy on 
local epidemiology and to perform careful evaluations of 
ACF implementation, yield and impact to improve the 
ACF evidence base.20 Today, ACF is considered a global 
health priority.21 22
Components
According to WHO,1 the main components of ACF 
include (1) having high- quality TB diagnosis, treatment, 
care, management and support for patients, as well as the 
capacity to scale these up (if needed), before screening 
is initiated; (2) prioritising risk groups; (3) choosing a 
suitable screening algorithm; (4) following established 
ethical principles; (5) optimising synergies with the 
delivery of other health and social services and (6) moni-
toring and reassessing ACF approaches.
The components of ACF, as well as those of the wider 
health system that ACF depends on, are well described 
in the literature. It is important for high- quality diag-
nosis, treatment, care, management, patient support and 
capacity for scale- up to be available.19 Risk groups must 
be prioritised based on assessments of benefits and risks, 
feasibility, acceptability, the number needed to screen to 
detect a case of TB and the cost- effectiveness of ACF,19 
while also considering the heterogeneity of the risk 
group.23
The overall ACF approach must be flexible, patient- 
centred15 24 and culturally sensitive.25 In resource poor 
settings, ACF is often backed by multichannel financing 
mechanisms, including from international donors.26 
Record- keeping, monitoring and evaluation are described 
as being essential.27 28 Incentives are sometimes deemed 
necessary, for example, for health workers,5 29 labora-
tory technicians,30 screening participants11 31–35 and TB 
patients.29 35 36 The articles also emphasised ACF- specific 
health education as paramount—for patients,31 37–39 their 
families,40 providers24 and community health workers 
(CHW).36 37 The training of CHWs should be followed 
by supervision.41 42 In addition, community involve-
ment32 39 42 43 and social mobilisation29 are major parts 
of ACF. One study described how the involvement of 
community leaders was a key component to improve trust 
among patients and contacts.31
Finally, the studies underlined how vital it is to collab-
orate with other disease programmes,33 34 43 agencies 
and sectors26 27 and to integrate ACF within existing 
systems.18 44 The latter includes collaboration between 
providers and community- based organisations,43 and 
between HIV and TB services.45
Influencing factors
In the following section, we summarise influencing 
factors for ACF policy development and implementation. 
We chose to speak of ‘influencing factors’ rather than 
facilitators and barriers, as one and the same factor might 
be a facilitator in one context and a barrier in another, for 
example, health workers’ satisfaction might be a powerful 
facilitator for ACF,42 while the lack thereof could be a 
strong barrier as well.46
Influencing factors for ACF policy development
ACF policy development processes were not well 
described in the literature. Policy development comprises 
the investment of governments and donors in ACF. Only 
two articles reported facilitators and/or barriers for ACF 
policy development: politics46 47 and laws.47 Welshman46 
describes how, in the mid- 1950s, the Ministry of Health 
in the United Kingdom subverted pressure from stake-
holders who were in favour of compulsory ACF at ports of 
entry—the Ministry ‘argued that the problem (of TB in 
migrants) was a minor one’ so a policy was not developed. 
On the other hand, laws such as the 1958 Commonwealth 
Migration Act were described, which made screening 
compulsory, and thus influenced ACF policy develop-
ment in the UK.47
Influencing factors for ACF policy implementation
Policy implementation processes in the area of ACF are 
widely researched. In total, 43 articles reported barriers 
and/or facilitators for ACF implementation (table 2). 
Most articles mentioned factors at the level of the health 
system, as well as the individual and community level.
health system level
It is fundamental to consider health system factors when 
putting ACF policy into practice and identifying which 
factors influence ACF policy implementation the most. 
We derived six major themes from the articles: (1) avail-
ability of financial resources, (2) existing systems and 
structures, (3) availability of diagnostic tests, (4) staff 
experience and motivation, (5) collaboration between 
different actors and (6) implementation of a person- 
centred approach.
 Availability of financial resources
Many articles (35%, n=15/43) mentioned financial 
resources as an influencing factor for ACF policy imple-
mentation. Finances were described as being scarce at 
different levels of the health system,40 for the provision of 
staff,39 42 drugs and equipment.48
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 Existing systems and structures
Existing systems and structures were reported as influ-
encing factors for ACF policy implementation by 26% 
(n=11/43) of the articles. Studies elaborated on the avail-
ability of health and social services14 19 and laboratory 
networks21 that could be used for ACF implementation.
Availability of diagnostic tests of sufficient sensitivity and 
specificity
Nineteen percent (n=8/43) of the articles elaborated 
on the availability of diagnostic tests and services as key 
influencing factor for ACF policy implementation—with 
many articles referring to the availability of molecular 
diagnostic tests such as Xpert MTB/RIF.27 36 49 50 Decen-
tralisation of healthcare services, national coverage of 
diagnostics and task sharing were perceived as facilitators 
of ACF policy implementation, but unavailable in many 
settings.33
 Staff experience and motivation
Thirty- three percent (n=14/43) of the studies described 
staff experience and motivation as influencing factors for 
ACF policy implementation. One study elaborated on 
how, on the one hand, staff members would feel moti-
vated by increased case detection and awareness- raising 
through ACF. On the other hand, they would be frus-
trated when being ‘shouted at, ignored, (and) harassed’ 
by target communities, in this case people living in 
poor urban settlements.39 The over- burdening of staff 
was highlighted by 16% (n=7/43) of the articles, for 
example, leading to absenteeism,51 and thus inhibiting 
ACF implementation.
 Collaboration between different actors
A variety of studies (16%, n=7/43) described collabora-
tion as an important influencing factor for ACF policy 
implementation. One example is the collaboration 
between community workers, health centre staff and labo-
ratory technicians in delivering diagnostic services as part 
of ACF.16 Moreover, Akkerman et al described the posi-
tive impact on diagnostic accuracy and the proportion 
of follow- up medical interventions when there is close 
collaboration with a limited number of experienced, 
high- volume chest radiograph readers when screening 
asylum seekers and other high- risk groups.52
 Implementation of a person-centred approach
The need for a person- centred approach to ACF policy 
implementation was referred to by 19% (n=8/43) 
of the articles, for example, adopting approaches 
including healthcare providers being non- judgemental 
and supportive of patients and their families during 
diagnosis and follow- up,53 and assuring confidenti-
ality.22 52 Another 12% (n=5/43) of the articles empha-
sised health education for the general public, screening 
participants, as well as TB patients and their families as 
a necessity.
 Individual and community
ACF policies should be for individuals and communi-
ties and their influence on successful implementation 
is elaborately described in the literature. Three overar-
ching themes emerged from the studies: (1) stigma and 
discrimination, (2) individual characteristics and socio-
cultural factors and (3) knowledge and awareness.
 Stigma and discrimination
Many studies (37%, n=16/43) reported stigma and 
discrimination linked to TB as influencing factors for 
ACF policy implementation. The consequences could 
be the avoidant behaviour of a contact of an index TB 
case, such as providing incorrect phone numbers and/
or wrong directions to their homes,14 or misconceptions 
about TB.24 43 Issues of fear, either of TB disease,23 39 53 the 
process of ACF,54 or the wider implications of being identi-
fied as a TB case, for example, through migrant screening 
programmes, where being diagnosed with TB case has in 
some instances resulted in deportation.34 38 55 56 Studies 
also reported the lack of trust of patients and their fami-
lies as key barrier for ACF policy implementation41 51—not 
only for early diagnosis, but for the sustained commit-
ment to addressing social determinants of TB.57
 Individual characteristics and sociocultural factors
Twenty- eight percent (n=12/43) of the articles mentioned 
the social characteristics of the persons screened as key 
influencing factors for ACF policy implementation, for 
example, for ensuring equitable access to care21 39 58 and 
promoting conducive health- seeking behaviour.23 41 43 
Moreover, the articles frequently reported sociocultural 
factors and language (33%, n=14/43) as influencing 
factors for ACF policy implementation. Culture was 
commonly described as a barrier to ACF policy implemen-
tation,34 41 59 for example, if cultural beliefs would nega-
tively influence the receptiveness to community health 
workers’ advice. Only one study mentioned culture as a 
facilitator for putting ACF into practice, for example, if 
culture meant respect towards professional authority.59
 Knowledge and awareness
Finally, 19% (n=8/43) of the articles reported factors 
related to knowledge and awareness as influencing factors 
for ACF policy implementation. One such factor could be 
the understanding of the purpose of ACF.24 Also, knowl-
edge and awareness are closely linked to persisting stigma 
and discrimination, for example, Ayakaka et al14 describe 
how health workers attributed TB- associated stigma to a 
lack of general knowledge in the community about TB.
DISCuSSIOn
Characteristics of the included articles
We identified 73 articles addressing antecedents, compo-
nents and/or influencing factors for ACF policy devel-
opment and implementation. The included studies 
originated from all WHO regions. Africa and Asia are 
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home to 90% of the 30 high TB burden countries (53% 
and 37%, respectively),89 which may explain why studies 
were more frequently conducted in these continents: 
22% of the studies were conducted in Africa, 12% in the 
Western- Pacific region and 7% in South- East Asia. Studies 
conducted in the European region (23%) were predomi-
nantly about different forms of migrant screening. There 
was no study from Latin America among the 73 included 
articles, and there were no articles in the Spanish language 
among those excluded.
Most studies were published after 2010, which may be 
a result of programmes implementing WHO guidelines 
on systematic screening1 as well as the growing number 
of prevalence surveys in different settings.39 We classi-
fied 41% of the articles as quantitative, for example, 
cross- sectional and cohort studies, effectiveness and cost- 
effectiveness studies, randomised controlled trials and 
programme evaluations. The next most common study 
types were reviews (22%) and qualitative studies (12%). 
The first qualitative studies on our topic were published in 
2003.24 54 We only identified two mixed- methods studies, 
one published in 201342 and one in 2015.39 The mixed- 
methods design combined with quantitative ACF evalua-
tion might become more commonly used to explore the 
complexity of ACF policy development and implementa-
tion in the future, as it has the potential to both increase 
contextual understanding and reduce biases.
Among the broad range of possible target groups for 
ACF, most of the articles focused either on TB contacts 
or migrants. The focus on the latter was mainly in low- 
incidence countries and may be a result of long- standing 
national health and migration policies supporting these 
types of screening. Yet, other studies covered vulnerable 
groups, such as homeless people, people living with HIV 
or people living in congregate settings, as well as the 
urban poor. Some articles included analysis of more than 
one high- risk group. There were no studies on indis-
criminate mass screening. However, there were studies 
targeting broad communities, for example, communities 
with high HIV prevalence.
Antecedents
Despite the growing number of studies (eg, operational 
studies), there is still a relative lack of evidence about 
the health benefits for individuals, the epidemiological 
impact and cost- effectiveness of different ACF approaches. 
Nonetheless, the interest in ACF has clearly increased in 
recent years. The persistent case detection gap, the 2013 
WHO guidelines on systematic screening1 and ACF being 
mentioned as a core component of the End TB Strategy2 
seem to have motivated countries to include ACF in 
national TB strategies. Universal Health Coverage and 
the Sustainable Development Goals have only margin-
ally been mentioned as important for stepping up the 
TB response.33 However, the Sustainable Development 
Goals—which aim to ‘leave no one behind’—might have 
contributed to a greater interest in ACF to leave no undi-
agnosed TB patients behind.
Not having enough evidence to drive ACF policy devel-
opment and implementation means that decisions to 
embark on ACF rely largely on stakeholders’ tacit knowl-
edge, experience, values and preferences. Demonstrated 
screening yield in the same or other settings could also 
motivate further ACF implementation, although the 
number of cases detected may not be a relevant public 
health impact measure in itself. The above- mentioned 
WHO guidelines use the term ‘indirect evidence’.1 
Strong ‘direct evidence’ exists that early diagnosis and 
correct TB treatment reduce morbidity, mortality and 
transmission. This can constitute, for example, ‘indirect 
evidence’ for ACF, based on the logic that if ACF leads to 
early detection and treatment, then it should also lead to 
better health outcomes and less transmission, despite the 
lack of trial data demonstrating a direct health impact of 
ACF. Similar reasoning can be used to describe potential 
harms associated with ACF, for example, based on model-
ling of the risk of false positive TB diagnoses in different 
epidemiological contexts. ‘Indirect evidence’, tacit knowl-
edge, experience, values and preferences are likely to be 
important antecedents for national policy.
Components
The components of ACF policy, and of the system which 
ACF is part of, are complex. The articles reported on 
the prerequisites of the given system, its resources,46 
capacity30 42 and tools.90 However, they also elaborated on 
the need for integrating ACF into health systems,41 60 as 
well as educating and engaging healthcare providers,5 21 
communities,12 29 39 44 screening participants35 and TB 
patients and their families25 34 35 for ACF implementa-
tion to succeed. All components seem indispensable for 
successful ACF policy development and implementation. 
Yet, in real- life settings, rarely all components are in place.
Which ACF components are essential and which are 
non- essential? The 2013 WHO guidelines on systematic 
screening list six key principles for screening for active 
TB, the first principle being: ‘Before screening is initiated, 
high- quality TB diagnosis, treatment, care, management 
and support for patients should be in place, and there 
should be the capacity to scale these up further to match 
the anticipated rise in case detection that may occur as 
a result of screening’.1 Yet, countries might not even 
completely adhere to this very first principle, for example, 
due to a lack of resources, before a country embarks on 
ACF policy development and implementation.
Influencing factors
 Scarce research on ACF policy development
Our findings indicate a paucity of research focusing 
specifically on ACF policy development. The only two 
factors described— politics and laws—were mentioned by 
the same author in two different articles and concerned 
migrant TB screening in a low- incidence country.46 47
Even though not documented as such in the litera-
ture, data on the epidemiological situation of a country 
and local evidence regarding impact are assumed to be 
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key factors influencing ACF policy development.1 These 
types of data and evidence are needed to identify high- 
risk groups90 and devise appropriate screening algo-
rithms. An assessment of the epidemiological situation 
might be based on data from regularly collected data sets 
or prevalence surveys, and WHO has developed a tool to 
help countries estimate screening yield and costs based 
on such data to identify appropriate risk groups and 
approaches.91
Interestingly, the evolution of the funding landscape 
for ACF, for example, through TB REACH, has not been 
explicitly mentioned as an influencing factor for ACF 
policy development or implementation, though it has 
been a likely game- changer. TB REACH is a case- finding 
initiative funded largely by Global Affairs Canada and 
coordinated by the Stop TB Partnership.92 The initia-
tive has both funded ACF activities and raised awareness 
about the importance of ACF. It has contributed to the 
local evidence base, while the uptake of the evidence 
generated by TB REACH may be considered but not 
mentioned in the studies included in this review. Four arti-
cles mentioned TB REACH as funder of their research, 
with the disclaimer that the initiative had no role in 
study design, data collection and analysis.16 42 60 61 Other 
publications acknowledged its role in implementing ACF 
when describing the study methods, for example, that TB 
REACH funded door- to- door screening39 or the imple-
mentation of different ACF models62 and that the initiative 
upgraded an ACF strategy by introducing new diagnostics 
which still have limited availability in many settings (eg, 
Xpert MTB/RIF).36 It is important to reflect on and docu-
ment the influence that TB REACH, other international 
funding mechanisms and technical agencies have on ACF 
policy development and implementation.
 ACF policy and social determinants of health
Many barriers and facilitators for implementing ACF 
policies lie at the level of communities and individuals. 
These factors include social determinants such as the 
educational level,14 35 employment status27 63 and access to 
care64 of the target population. These factors can limit an 
individual’s or a community’s participation in ACF. ACF 
policies cannot be put in practice successfully if imple-
mentation barriers prevail. However, rather than talking 
about ‘missing cases’ and communities that are ‘hard to 
reach’, it may be useful to consider if health services are 
missing or hard to reach instead.
Individuals or communities may be ACF target groups 
precisely because health services are missing or hard 
to reach. As such, ACF could be a way to by- pass access 
barriers, for example, by using mobile units. Yet, even 
when designing services to be more accessible, target 
populations may still not come forward, take the next step 
of referral to complete the diagnostic pathway or adhere 
to treatment due to socioeconomic barriers.
We argue that ACF polices thus must be designed 
and implemented with careful consideration of social 
determinants in a given context to avoid possible harm. 
Whitehead and Dahlgren93 described how interventions 
designed to help vulnerable populations may be ‘imple-
mented in such a way as to stigmatize the very people the 
programme was designed to help and, in so doing, push 
them to avoid the help on offer.’
 A comprehensive view on ACF policies
A comprehensive approach in developing and imple-
menting ACF policies is required that includes health 
education as an important component to ACF policies, 
and that ensures collaboration between key stakeholders, 
both between patients and providers, and between 
providers and local health authorities, between agencies, 
and across sectors and disease programmes.
Although this review focused on the factors that influ-
ence ACF policy and implementation, it is important to 
also reflect on how ACF policy influences its context in 
return, for example, not only factors at the level of the 
community and the individual, but at the level of the 
health system and beyond; How may the ACF policy 
increase or decrease stigma in a community? How may 
ACF policy influence the human and financial resources 
available in a health system? Only then may we see the real 
impact of ACF and be able to make equitable decisions in 
policy development and implementation processes.
 Future research
This scoping review demonstrated that while we know 
much about facilitators and barriers for ACF policy 
implementation, we know less about how to strengthen 
those facilitators and how to overcome those barriers. A 
major knowledge gap remains when it comes to under-
standing which contextual factors influence ACF policy 
development.
limitations
Our scoping review has some limitations. To increase the 
feasibility, we limited the search to MEDLINE, Web of 
Science, The Cochrane Database of Systematic Reviews 
and the WHO Library. We did not do a critical appraisal 
of the individual sources of evidence or within sources 
of evidence, nor did we describe sources of funding for 
the included sources of evidence. Such appraisals and 
descriptions would have allowed us to discover the scar-
city of research and to characterise the quality of and 
gaps in the evidence base and enable the development 
of robust recommendations. We leave these questions for 
future systematic reviews to address.
We acknowledge that we may have been able to provide 
a more in- depth overview of antecedents, components 
and influencing factors for ACF policy development 
and implementation by including additional databases, 
searching grey literature and references of included 
studies, and contacting authors for more information, 
which could be included in a future systematic review. 
However, we believe that our review still adds value to the 
current body of knowledge on ACF, by providing collated 
and comprehensive insights into the peer- reviewed 
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scientific literature. We also limited the inclusion to 
studies written in English, which may have resulted in 
the exclusion of eligible studies in other languages, for 
example, Spanish. Furthermore, the results from this 
scoping review are only up to date as of 31 January 2018. 
The data were extracted by one reviewer only. However, 
the data are likely valid, as a pilot- test was conducted prior 
to embarking on data extraction with members of the 
study team. A second reviewer verified a random selec-
tion of the data.
Another limitation was that the included articles 
often did not distinguish between the implementation 
of an ACF policy versus the implementation of an ACF 
programme or intervention. This is likely due to inconsis-
tent use of the terms in the literature. As such, our results 
are likely applicable to both. Furthermore, the reporting 
of ACF policy development and implementation varied 
in their completeness across the included articles, and 
as such, our data are limited by the details described in 
the literature, for example, most papers described steps 
to implementation, but did not provide details on non- 
response or unsuccessful practices. There is a risk of 
publication bias.
COnCluSIOnS
We identified some main themes regarding the anteced-
ents, components and influencing factors for ACF policy 
development and implementation. However, evidence 
remains scarce especially concerning policy development. 
Research on ACF is required to understand, inform and 
improve policy development and implementation.
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